March 2024 Patent Highlights: OX2R Agonists, TEAD Covalent Inhibitors, NaV1.8 Inhibitors, LRRK2 Inhibitors, and More

In this article, you'll find a curated selection of >70 molecules from August that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.

In this article, you'll find a curated selection of nearly 50 molecules from July that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.

To streamline your review of the patent literature, we've distilled thousands of new documents into a searchable table featuring over 200 selected patents focused on key areas in drug discovery, all published in July 2024. Each patent includes commentary for easier navigation and understanding.

This article highlights a patent application from Arvinas that discloses the biological activity of compounds that act as tau-targeting heterobifunctional degraders, providing a summary of key data for selected molecules disclosed in the patent application.

This summary of September's major clinical updates features FDA approvals, drug withdrawals, anticipated regulatory decisions, notable trial results, new NDA submissions, clinical trial setbacks, and the initiation of new clinical trials.